JAZZ Stock Analysis: Jazz Pharmaceuticals | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 14.449m USD | 12M Return: 122.5% | Charts, Fundamentals & Technical Analysis

Sleep Disorders, Epilepsy, Oncology, Rare Diseases

Total Rating 59

Safety 76

Buy Signal 1.25

Biotechnology
Industry Rotation: +16.7

Market Cap: 14.4B
Avg Turnover: 205M

Risk 3d forecast

Volatility30.8%

VaR 5^th Pctl5.03%

VaR vs Median-0.82%

Reward TTM

Sharpe Ratio2.20

Rel. Str. IBD91.4

Rel. Str. Peer Group77.2

Character TTM

Beta0.455

Beta Downside-0.050

Hurst Exponent0.547

Drawdowns 3y

Max DD32.71%

CAGR/Max DD0.80

CAGR/Mean DD1.86

EPS (Earnings per Share)

EPS CAGR: -26.50%
EPS Trend: -53.2%

Last SUE: 0.95
Qual. Beats: 1

Revenue

Rev. CAGR: 5.58%
Rev. Trend: 97.4%

Last SUE: 2.38
Qual. Beats: 1

Warnings

Interest Coverage Ratio Critical

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 10.5 years of data

Jan +0.8% 0

Feb +2.5% 14

Mar +2.5% 15

Apr +0.7% 0

May -2.2% 14

Jun -0.0% 0

Jul +0.0% 0

Aug -1.1% 0

Sep -1.5% 27

Oct +0.1% 0

Nov -0.8% 0

Dec -0.6% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: JAZZ Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a Dublin, Ireland-headquartered specialty biopharmaceutical company founded in 2003 that identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and other international markets. Listed on NASDAQ since June 2007, the company sits within the Health Care sector and, as a Large Cap (approximately $14B market capitalization), operates with a business model centered on specialty drug development, regulatory exclusivity, and commercialization in rare and serious disease areas.

Its marketed product portfolio is diversified across neurology (Xywav for cataplexy/EDS in narcolepsy and idiopathic hypersomnia; Epidiolex for seizures associated with LGS, Dravet syndrome, and tuberous sclerosis complex), oncology (Rylaze and Enrylaze for acute lymphoblastic leukemia/lymphoblastic lymphoma; Zepzelca for metastatic small cell lung cancer; Ziihera for HER2-positive biliary tract cancers; Modeyso for H3 K27M-mutant diffuse midline glioma; Vyxeos for certain AML indications), and hematology (Defitelio for severe veno-occlusive disease).

Jazz maintains a development pipeline spanning Phase 1 through Phase 3 trials, including Zanidatamab (HER2-positive gastroesophageal adenocarcinoma and biliary tract cancers), Dordaviprone (H3 K27M-mutant diffuse glioma), expanded Vyxeos indications, JZP3507 for pheochromocytoma/paraganglioma, and earlier-stage programs such as JZP815, JZP898, and JZP047. The company supplements its internal research through licensing and collaboration agreements with partners including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, and Werewolf Therapeutics.

Headlines to Watch Out For

Xywav revenue growth offsets Xyrem generic competition pressure
Epidiolex and Zepzelca sales expand rare disease oncology portfolio
Acquisition debt burden limits buyback and capital allocation flexibility

Piotroski VR-10 (Strict) 2.5

Net Income: 29.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA -2.40 > 1.0
NWC/Revenue: 52.64% < 20% (prev 71.47%; Δ -18.83% < -1%)
CFO/TA 0.11 > 3% & CFO 1.33b > Net Income 29.5m
Net Debt (2.60b) to EBITDA (544.1m): 4.79 < 3
Current Ratio: 2.04 > 1.5 & < 3
Outstanding Shares: last quarter (66.1m) vs 12m ago 8.40% < -2%
Gross Margin: 84.12% > 18% (prev 88.81%; Δ -4.70% > 0.5%)
Asset Turnover: 37.95% > 50% (prev 35.24%; Δ 2.71% > 0%)
Interest Coverage Ratio: -0.07 > 6 (EBIT TTM -14.4m / Interest Expense TTM 204.6m)

Altman Z'' 2.19

A: 0.20 (Total Current Assets 4.58b - Total Current Liabilities 2.25b) / Total Assets 11.9b
B: 0.08 (Retained Earnings 939.2m / Total Assets 11.9b)
C: -0.00 (EBIT TTM -14.4m / Avg Total Assets 11.7b)
D: 0.62 (Book Value of Equity 4.53b / Total Liabilities 7.33b)
Altman-Z'' = 2.19 = BBB

Beneish M -2.81

DSRI: 1.17 (Receivables 836.3m/653.0m, Revenue 4.44b/4.06b)
GMI: 1.06 (GM 88.81% / 84.12%)
AQI: 0.95 (AQ_t 0.59 / AQ_t-1 0.62)
SGI: 1.09 (Revenue 4.44b / 4.06b)
TATA: -0.11 (NI 29.5m - CFO 1.33b) / TA 11.9b)
Beneish M = -2.81 (Cap -4..+1) = A

What is the price of JAZZ shares?

As of July 04, 2026, the stock is trading at USD 243.47 with a total of 766,800 shares traded. Over the past week, the price has changed by +7.63%, over one month by +5.43%, over three months by +30.30% and over the past year by +122.45%.

Current recommended Stop Loss: 234.70 (which is 3.6% or 1.3 ATR below the current price).

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.

StrongBuy: 10
Buy: 6
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the JAZZ price?

Analysts Target Price	257	5.6%

Jazz Pharmaceuticals (JAZZ) - Fundamental Data Overview as of 28 June 2026

Market Cap USD = 14.4b (14.4b USD * 1.0 USD.USD)
P/E Trailing = 1916.8334
P/E Forward = 12.5471
P/S = 3.2553
P/B = 3.1881
P/EG = 0.9582
Revenue TTM = 4.44b USD
EBIT TTM = -14.4m USD
EBITDA TTM = 544.1m USD
Long Term Debt = 4.32b USD (from longTermDebt, last quarter)
Short Term Debt = 1.05b USD (from shortTermDebt, last quarter)
Debt = 5.48b USD (from shortLongTermDebtTotal, last quarter) + Leases 62.2m
Net Debt = 2.60b USD (calculated: Debt 5.48b - CCE 2.87b)
Enterprise Value = 17.1b USD (14.4b + Debt 5.48b - CCE 2.87b)
Interest Coverage Ratio = -0.07 (Ebit TTM -14.4m / Interest Expense TTM 204.6m)
EV/FCF = 13.69x (Enterprise Value 17.1b / FCF TTM 1.25b)
FCF Yield = 7.30% (FCF TTM 1.25b / Enterprise Value 17.1b)
FCF Margin = 28.06% (FCF TTM 1.25b / Revenue TTM 4.44b)
Net Margin = 0.66% (Net Income TTM 29.5m / Revenue TTM 4.44b)
Gross Margin = 84.12% ((Revenue TTM 4.44b - Cost of Revenue TTM 705.1m) / Revenue TTM)
Gross Margin QoQ = 71.34% (prev none%)
Tobins Q-Ratio = 1.44 (Enterprise Value 17.1b / Total Assets 11.9b)
Interest Expense / Debt = 3.74% (Interest Expense 204.6m / Debt 5.48b)
Taxrate = 2.04% (6.10m / 299.2m)
NOPAT = -14.1m (EBIT -14.4m * (1 - 2.04%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 4.58b / Total Current Liabilities 2.25b)
Debt / Equity = 1.21 (Debt 5.48b / totalStockholderEquity, last quarter 4.53b)
Debt / EBITDA = 4.79 (Net Debt 2.60b / EBITDA 544.1m)
Debt / FCF = 2.09 (Net Debt 2.60b / FCF TTM 1.25b)
Total Stockholder Equity = 4.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.25% (Net Income 29.5m / Total Assets 11.9b)
RoE = 0.71% (Net Income TTM 29.5m / Total Stockholder Equity 4.13b)
RoCE = -0.17% (EBIT -14.4m / Capital Employed (Equity 4.13b + L.T.Debt 4.32b))
RoIC = -0.14% (negative operating profit) (NOPAT -14.1m / Invested Capital 10.4b)
WACC = 6.50% (E(14.4b)/V(19.9b) * Re(7.58%) + D(5.48b)/V(19.9b) * Rd(3.74%) * (1-Tc(0.02)))
Discount Rate = 7.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.43 | Cagr: -3.79%
[DCF] Terminal Value 73.10% ; FCFF base≈1.34b ; Y1≈1.18b ; Y5≈951.4m
[DCF] Fair Price = 201.6 (EV 15.3b - Net Debt 2.60b = Equity 12.7b / Shares 62.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -53.23 | EPS CAGR: -26.50% | SUE: 0.95 | # QB: 1
Revenue Correlation: 97.38 | Revenue CAGR: 5.58% | SUE: 2.38 | # QB: 1
EPS current Quarter (2026-06-30): EPS=6.18 | Chg30d=+0.91% | Revisions=+35% | Analysts=16
EPS next Quarter (2026-09-30): EPS=6.39 | Chg30d=+0.73% | Revisions=-24% | Analysts=16
EPS current Year (2026-12-31): EPS=25.39 | Chg30d=+0.29% | Revisions=+47% | GrowthEPS=+203.0% | GrowthRev=+5.8%
EPS next Year (2027-12-31): EPS=25.61 | Chg30d=+0.39% | Revisions=+35% | GrowthEPS=+0.9% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: +27% (up=36, down=20)